Simplify CAR T cell manufacturing with LNP-mediated delivery of base editing tools

Looking to streamline your CAR T cell process? Discover how lipid nanoparticles (LNP) deliver base editing tools to generate fratricide-resistant CD45-edited CAR45 T cells. This approach enables more efficient, scalable, and potentially universal therapies for blood cancer, without compromising precision and potency.

Rethink your cell therapy manufacturing process. Register now and be part of the future.

Presented by: Friederike Herbst-Nowrouzi, Principal Investigator, Director of Human Genome Editing Laboratory, University of Pennsylvania

Moderated by: Shell Ip, Manager, Client Learning and Scientific Content, Cytiva

Rethink cell therapy delivery with LNPs. Get a helping hand at https://cytiva.link/czpwj.

Originally presented at the Cytiva RNA-LNP Virtual Summit in September 2024.